Search Result
Results for "
α-glucosidases
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-117721
-
-
-
- HY-B0481
-
|
BAY1099; BAY-m1099
|
Glucosidase
AMPK
Reactive Oxygen Species
|
Metabolic Disease
|
|
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
|
-
-
- HY-124662
-
|
|
Flavivirus
Dengue virus
Glucosidase
|
Infection
|
|
IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy .
|
-
-
- HY-149342
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-29 (compound 19) is a α-glucosidases inhibitor (IC50=1.21 μM, Ki=1.80 μM). α-Glucosidase-IN-29 ca be used for research of diabetes and related diseases .
|
-
-
- HY-113585
-
|
|
Others
|
Others
|
|
1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride is a naturally occurring pyrrolidine alkaloid that acts as an inhibitor of glycogen phosphorylase and α-glucosidases, and is sourced from Arachniodes standishii and Angylocalyx boutiqueanus.
|
-
-
- HY-117603
-
|
|
Glucokinase
|
Infection
|
|
CM-10-18 is a potent and orally active inhibitor of both α-glucosidases I and II in vitro and in treated animals. CM-10-18 inhibits DENV infection of cultured human cells and reduces the peak viremia of DENV in mice .
|
-
-
- HY-145275
-
|
|
Glucosidase
|
Infection
|
|
EB-0176 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.6439 and 0.0011 μM, respectively. EB-0176 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0176 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses .
|
-
-
- HY-145274
-
|
|
Glucosidase
|
Infection
|
|
EB-0156 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.0479 and less than 0.001 μM, respectively. EB-0156 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0156 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses .
|
-
-
- HY-150560
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .
|
-
-
- HY-156078
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive and orally active α-glucosidase inhibitor with an IC50 value of 3.07 μM. α-Glucosidase-IN-32 complex with α-glucosidase through hydrogen bonds and hydrophobic interactions, led to changes in the conformation and secondary strictures of α-glucosidase and further the inhibition of the enzymatic activity. α-Glucosidase-IN-32 can be used for diabetic disease research .
|
-
-
- HY-157489
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-47 (compound 8H) is a non-competitive α-glucosidase (α-glucosidase) inhibitor with IC50 value is 38.2 μM and Ki value is 38.2 μM. α-Glucosidase-IN-47 can be used in diabetes research. .
|
-
-
- HY-148575
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .
|
-
-
- HY-161522
-
|
|
Glucosidase
Carbonic Anhydrase
|
Endocrinology
|
|
α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective. .
|
-
-
- HY-162286
-
-
-
- HY-162287
-
-
-
- HY-149341
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-28 (Compound 18) is a α-Glucosidase inhibitor (IC50: 0.62 μM, Ki: 3.93 μM). α-Glucosidase-IN-28 binds to α-glucosidase at the original binding site (OBS), and forms multiple hydrophobic interactions with nearby amino acids. α-Glucosidase-IN-28 can be used for research of diabetes and related diseases .
|
-
-
- HY-115978
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC50 of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .
|
-
-
- HY-N11512
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-24 (Compound 13) is an α-Glucosidase inhibitor with an IC50 of 451 μM. α-Glucosidase-IN-24 can be isolated from Swertia kouitchensis .
|
-
-
- HY-155372
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-39 is a potent inhibitor of α-glucosidase enzyme with an IC50 of 869.06 ppm. α-Glucosidase-IN-39 can used in study antidiabetic .
|
-
-
- HY-163066
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-44 (compound IT4) is an inhibitor of α-glucosidase with IC50 value of 2.35 μM. α-Glucosidase-IN-44 has an oral activity. α-Glucosidase-IN-44 suppresses fasting blood glucose levels in diabetic mice .
|
-
-
- HY-161999
-
|
|
Glucosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-73 (compound 16b) is an α-Glucosidase inhibitor with IC50 of 0.158 μM. α-Glucosidase-IN-73 can activate PPAR γ. α-Glucosidase-IN-73 can be used in anti-diabetic and anti-inflammatory studies .
|
-
-
- HY-149579
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-36 (compound 5g) is a potent α-glucosidase inhibitor, with an IC50 of 6.69 ± 0.18 μM, Ki and Kis of 1.65 μM and 4.54 μM, respectively. α-Glucosidase-IN-36 may inhibit α-glucosidase activity by binding with its active site as well as changing the secondary structure of α-glucosidase. α-Glucosidase-IN-36 can be used for type 2 diabetes mellitus (T2DM) research .
|
-
-
- HY-W783267
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-35 (compound 1) is a kind of chromene. α-Glucosidase-IN-35 can be isolated from the aqueous extract of the aerial parts of Brickellia cavanillesii. α-Glucosidase-IN-35 is a potent inhibitor of α-glucosidase with an IC50 value of 0.169 mg/mL .
|
-
-
- HY-147823
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-6 (compound 18) is a competitive α-glucosidase inhibitor with an IC50 of 5.69 µM. α-Glucosidase-IN-6 has anti-diabetic potential .
|
-
-
- HY-157488
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-46 is a potent α-glucosidase inhibitor with an IC50 of 26.0 μM. α-Glucosidase-IN-46 can be used for the research of type 2 diabetes .
|
-
-
- HY-161318
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-52 (Compound 3h) is an α-glucosidase inhibitor with an IC50 of 2.8 μM. α-Glucosidase-IN-52 can be used for diabetes research .
|
-
-
- HY-149668
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-41 (compound 5o) is a potent α-glucosidase inhibitor. α-Glucosidase-IN-41 can arise the changed secondary structure of α-Glu to hinder enzyme catalytic activity. α-Glucosidase-IN-41 can be used for diabetes mellitus research .
|
-
-
- HY-149676
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-42 (Compound 26) is a 9-O-berberrubine carboxylate derivative. α-Glucosidase-IN-42 has potent α-glucosidase inhibitory activities with an IC50 value in the range of 1.61 μM. α-Glucosidase-IN-42 can be used for the research of antidiabetic .
|
-
-
- HY-161764
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC50 values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes .
|
-
-
- HY-147718
-
|
|
Glutaminase
|
Metabolic Disease
|
|
α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC50 of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus .
|
-
-
- HY-151142
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM. α-Glucosidase-IN-18 has antidiabetic activity .
|
-
-
- HY-147964
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC50 of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research .
|
-
-
- HY-147965
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC50 of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research .
|
-
-
- HY-151141
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.79 μM. α-Glucosidase-IN-17 shows antidiabetic activity .
|
-
-
- HY-151135
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-15 (Compound 14B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.34 μM. α-Glucosidase-IN-15 shows antidiabetic activity .
|
-
-
- HY-151145
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity .
|
-
-
- HY-151143
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .
|
-
-
- HY-151144
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity .
|
-
-
- HY-157311
-
|
|
Glucosidase
|
Cancer
|
|
α-Glucosidase-IN-45 (compound 11E) is an inhibitor of α-glucosidase. α-Glucosidase-IN-45 is a novel indol-fused pyrano[2,3-D]pyrimidine compound .
|
-
-
- HY-N12664
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-54 (compound 2) is a α-glucosidase inhibitor with the IC50 of 0.011 mM, and can be isolated form Syzygium jambos (L.). α-Glucosidase-IN-54 can be used for study of diabetes .
|
-
-
- HY-158697
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-65 (compound 5) is a Schiff base derivative of 3,4-dihydroxyphenylacetic acid. α-Glucosidase-IN-65 is a potent α-glucosidase inhibitor, with an IC50 of 12.84 μM .
|
-
-
- HY-169251
-
-
-
- HY-146225
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC50 values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .
|
-
-
- HY-N12689
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-56 (compound 1) is an orally active, potent α‐glucosidase inhibitor with an IC50 value of 45.86 μM. α-Glucosidase-IN-56 has potent anti-glycation activities .
|
-
-
- HY-146156
-
-
-
- HY-150960
-
-
-
- HY-155344
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC50 of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM) .
|
-
-
- HY-162541
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-64 (compound 10) is a potent α-glucosidase inhibitor with an IC50 value of 8.62 µM. α-Glucosidase-IN-64 is a polycyclic polyprenylated acylphloroglucinol that can be isolated from hypericum beanii .
|
-
-
- HY-162697
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-69 (compound 5k) is a competitive α-glucosidase inhibitor with an IC50 of 26.8 µM and a Ki value of 26.0 µM. α-Glucosidase-IN-69 has the potential for the diabetes research .
|
-
-
- HY-147711
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
- HY-154998
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-27 (compound 8l) is an α-glucosidase inhibitor (IC50=25.78 μM). α-Glucosidase-IN-27 has the potential to study type 2 diabetes (D2M) .
|
-
- HY-N12347
-
|
|
Others
|
Inflammation/Immunology
|
|
α-Glucosidase-IN-37 (Compound 11) moderately inhibits LPS-induced NO production with an IC50 value of 23.7 μM in macrophages. α-Glucosidase-IN-37 has weak inhibitory activity against α-Glucosidase .
|
-
- HY-150959
-
-
- HY-150961
-
-
- HY-162262
-
-
- HY-162395
-
-
- HY-147879
-
-
- HY-156447
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-40 (compound 5) is a noncompetitive α-glucosidase enzyme inhibitor with an IC50 of 24.62 μM .
|
-
- HY-151138
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .
|
-
- HY-149332
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .
|
-
- HY-149409
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC50 value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .
|
-
- HY-161281
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .
|
-
- HY-163907
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-71 (Compound 7h) is a competitive α-glucosidase inhibitor (IC50: 98.0 µM). α-Glucosidase-IN-71 can be used for research of carbohydrate-related diseases, especially type 2 diabetes mellitus .
|
-
- HY-161421
-
|
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-61 (Compd 1j), a competitive α-glucosidase inhibitor, demonstrates excellent inhibition with an IC50 of 0.73 μM. α-Glucosidase-IN-61 (Compd 1j) is used for the research of type 2 diabetes mellitus .
|
-
- HY-N13173
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-70 (compound 9) is an α-glucosidase inhibitor (IC50=31.1 μM) isolated from the traditional Chinese herbal medicine Swertia mussotii. α-Glucosidase-IN-70 can be used in the research of diabetes .
|
-
- HY-168594
-
|
|
Glucosidase
|
Neurological Disease
Metabolic Disease
|
|
α-Glucosidase/NLRP3-IN-1 (Compound 8) is a dual inhibitor of α-glucosidase and NLRP3, exhibiting an IC50 of 6.6 μM against α-glucosidase and inhibiting NLRP3 in multiple cell lines at a concentration of 100 μM. α-Glucosidase/NLRP3-IN-1 demonstrates neuroprotective and antidiabetic properties, and can be utilized in relevant research .
|
-
- HY-163975
-
|
|
Glucosidase
|
Cancer
|
|
α-Glucosidase-IN-72 (compound 5i) is a 2,4-dichloro-N-phenylacetamide derivative and an α-glucosidase inhibitor (IC50: 6 μM). α-Glucosidase-IN-72 does not follow Lipinski's "rule of five" and does not induce cancer .
|
-
- HY-169117
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-74 (Compound 7d), an isatin-thiazole derivative, is a α-glucosidase inhibitor. α-Glucosidase-IN-74 exhibits antidiabetic activity by decreasing glycaemia and triglyceride levels in Streptozotocin (HY-13753)-induced diabetic animals .
|
-
- HY-146981
-
-
- HY-163005
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
- HY-168185
-
|
|
Glucosidase
Phosphatase
Amylases
|
Metabolic Disease
|
|
α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC50 value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against α-amylase with an IC50 of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus .
|
-
- HY-161411
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-60 (Compound 5k) exhibits a competitive inhibitory efficacy against α-Glucosidase, with IC50 of 10.8 μM .
|
-
- HY-162169
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .
|
-
- HY-162390
-
|
|
Amylases
Glucosidase
|
Endocrinology
|
|
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC50 = 30.39 μM) and α-glucosidase (IC50 = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .
|
-
- HY-162639
-
|
|
Glucosidase
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
|
α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models .
|
-
- HY-161469
-
-
- HY-152158
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .
|
-
- HY-154972
-
|
|
Glucosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .
|
-
- HY-149557
-
|
|
Glucosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-155241
-
|
|
Glucosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-156380
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
|
-
- HY-162673
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of α-amylase and α-Glucosidase with IC50 values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .
|
-
- HY-N2223
-
|
Ganodermadiol
|
Glucosidase
|
Metabolic Disease
|
|
Ganoderol B is a potent α-glucosidase inhibitor. Ganoderol B has high α-glucosidase inhibition with an IC50 of 48.5 μg/mL (119.8 μM) .
|
-
- HY-162036
-
|
|
Glucosidase
Amylases
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC50 values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC50 values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .
|
-
- HY-163433
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .
|
-
- HY-P2802
-
|
α-D-Glucosidase, Yeast
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase, Yeast (α-D-Glucosidase, Yeast), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .
|
-
- HY-158037
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health .
|
-
- HY-146305
-
-
- HY-149532
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
- HY-149533
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
- HY-N0374
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Licochalcone C could inhibit α-glucosidase, with IC50s of <100 nM and 92.43 μM for α-glucosidase and protein tyrosine phosphatase 1B (PTP1B), respectively.
|
-
- HY-W011411
-
|
|
Glucosidase
|
Others
|
|
4-Nitrophenyl a-D-glucopyranoside is a chromogenic substrate for α-glucosidase. 4-Nitrophenyl a-D-glucopyranoside can be used to measure of α-glucosidase activity .
|
-
- HY-146984
-
|
|
Glucosidase
|
Inflammation/Immunology
|
|
α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
|
-
- HY-155030
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-25 (Compound (R)-8k) is a competitive inhibitor of α-glucosidase, with an IC50 of 1.19μM and can be used for anti-diabetic research .
|
-
- HY-N8120
-
-
- HY-155105
-
|
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-30 (compound 8c) is a potent, orally active, competitive inhibitor against α-glucosidase, with Ki of 40.0 µM and IC50 value of 49.0 µM. α-Glucosidase-IN-30 is non-cytotoxic against the cancer and normal cell lines MCF-7 and HDF, and can be used for Type 2 diabetes study .
|
-
- HY-125713
-
|
|
Glucosidase
Enterovirus
|
Infection
|
|
Ganoderic acid Y is a α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. Ganoderic acid Y inhibits enterovirus 71 (EV71) replication through blocking EV71 uncoating .
|
-
- HY-162634
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and α-amylase, with the IC50s of 21 μM and 61 μM, respectively .
|
-
- HY-161355
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes .
|
-
- HY-P2802B
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
α-Glucosidase, rice is a carbohydrase enzyme that catalyzes the release of α-glucose molecules. α-Glucosidase, rice retains exoglycosidases, which hydrolyze α-glucosidic linkage at the nonreducing end of a substrate .
|
-
- HY-U00090
-
|
MOR 14; N-Methyl-1-deoxynojirimycin; N-Methylmoranolin
|
Glucosidase
|
Metabolic Disease
|
|
N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
|
-
- HY-N3962
-
-
- HY-162373
-
|
|
Amylases
Glucosidase
P-glycoprotein
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
- HY-W005598
-
|
|
Glucosidase
|
Metabolic Disease
|
|
2-Hydroxyquinoline is a potent α-glucosidase inhibitor with IC50 values of 64.4, 130.5 µg/mL for α-glucosidase and α-amylase, respectively. 2-Hydroxyquinoline has the potential for the research of diabetes .
|
-
- HY-162635
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of α-amylase and α-glucosidase, with the IC50s of 45.53 μM and 27.73 μM, respectively .
|
-
- HY-163439
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .
|
-
- HY-P2802A
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
α-Glucosidase, bacillus stearothermophilus is a carbohydrase enzyme that catalyzes the release of α-glucose molecules. α-Glucosidase, bacillus stearothermophilus retains exoglycosidases, which hydrolyze α-glucosidic linkage at the nonreducing end of a substrate .
|
-
- HY-119593
-
-
- HY-N0466
-
-
- HY-165100
-
|
DG(16:1/0:0/16:1); 1,3-Dipalmitolein
|
Others
|
Others
|
|
1,3-Dipalmitoleoyl glycerol (DG(16:1/0:0/16:1)) is a compound isolated from sea cucumber viscera, which has α-glucosidase inhibitory activity and has different degrees of inhibitory effects on α-glucosidase from different sources.
|
-
- HY-145273
-
|
|
Glucosidase
|
Infection
|
|
EB-0150 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.73 and 0.0337 μM, respectively. EB-0150 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0150 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses . EB-0150 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-U00266
-
-
- HY-N1901
-
-
- HY-168058
-
|
|
Glucosidase
|
|
|
WXC-25 is an inhibitor of α-glucosidase with an IC50 value of 2.02 μM .
|
-
- HY-N1881
-
|
|
Lipoxygenase
Glucosidase
|
Others
|
|
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an Ki of 102.6 μM for soybean LOX-1 and an IC50 of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.
|
-
- HY-N12761
-
|
|
Phosphatase
Glucosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
Penpaxilloids A (Compound 1) is a non-competitive inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 8.60 μM. Penpaxilloids A can be isolated from the fungus Penicillium sp. ZYX-Z-143. Penpaxilloids A is also an α-glucosidase (α-glucosidase) inhibitor with anti-inflammatory activity .
|
-
- HY-N4258
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Panasenoside is a flavonoid isolated from Lilium pumilum DC. Panasenoside exhibits α-glucosidase inhibitory activity .
|
-
- HY-N3101
-
-
- HY-N3503
-
|
|
Glucosidase
|
Endocrinology
|
|
Ganoderlactone D shows inhibitory effects of yeast α-Glucosidase with IC50 values of 41.7 μM .
|
-
- HY-N12790
-
|
Ananonin B
|
Glucosidase
|
Metabolic Disease
|
|
Arisanschinin D (Ananonin B) is an α-Glucosidase inhibitor and can be isolated from Schisandra arisanensis Hay .
|
-
- HY-W009417
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Cedryl acetate is a tricyclic sesquiterpene isolated from the plant Cunninghamia lanceolata. Cedryl acetate shows α-glucosidase inhibitory activity .
|
-
- HY-W826489
-
|
α-Sophorose, 98%
|
Biochemical Assay Reagents
|
Others
|
|
D-Glucopyranose, 98% serves as a substrate for various glycosidase enzymes, including α-glucosidase, and is also used in glycobiology research.
|
-
- HY-131114
-
|
|
Others
|
Others
|
|
Valiolamine is an aminocyclitol. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase .
|
-
- HY-132179
-
-
- HY-N9317
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Tangshenoside I, isolated from the roots of Codonopsis lanceolata, exhibits weak α-glucosidase inhibitory activities in vitro with an IC50 of 1.4 mM .
|
-
- HY-N2929
-
|
|
Glucosidase
|
Cardiovascular Disease
|
|
β-Hydroxypropiovanillone, a natural compound, shows significant concentration-dependent inhibitory effects on α-glucosidase with an IC50 of 257.8 μg/mL .
|
-
- HY-N11530
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Kouitchenside G is a natural product that can be isolated from Swertia kouitchensis. Kouitchenside G inhibits α-Glucosidase with an IC50 of 956 μM .
|
-
- HY-108828
-
|
rhGAA
|
Others
|
Others
|
|
Alglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human α-glucosidase product. Alglucosidase alfa can be used for Pompe disease research .
|
-
- HY-E70183
-
|
EC:3.2.1.20; GAA
|
Biochemical Assay Reagents
|
Others
|
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
-
- HY-138992
-
|
|
Others
|
Others
|
|
2,3-Indolobetulin is a pentacyclic triterpene and a derivative of betulin. 2,3-Indolobetulin can be used in the synthesis of α-glucosidase inhibitors .
|
-
- HY-119821
-
|
|
Glucosidase
|
Infection
|
|
Terphenyllin is a naturally abundant p-terphenyl metabolite isolated from the coral derived fungus Aspergillus candidus, has significant α-glucosidase inhibitory activity .
|
-
- HY-131504A
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .
|
-
- HY-N10426
-
|
|
Glucosidase
|
Metabolic Disease
|
|
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC50 of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .
|
-
- HY-129131
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Chrysin 6-C-arabinoside 8-C-glucoside is a α±-glucosidase inhibitors which are widely used in the study for type 2 diabetes .
|
-
- HY-N1820
-
-
- HY-162637
-
|
|
Glucosidase
|
Metabolic Disease
|
|
CTL26 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 2.81 µM. CTL26 shows anti-diabetic efficacy .
|
-
- HY-N0466R
-
|
|
Endogenous Metabolite
Glucosidase
|
Others
|
|
Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is a steviol glycoside and α-glucosidase inhibitor with an IC50 of 35.01 ug/mL.
|
-
- HY-N7203
-
|
|
Glucosidase
|
Metabolic Disease
|
|
N-Caffeoyl O-methyltyramine is a class of alkaloid isolated from Cuscuta reflexa with strong inhibitory activity against α-glucosidase (IC50 of 103.58 μM) .
|
-
- HY-N1218
-
|
|
Glucosidase
Bcl-2 Family
|
Others
|
|
Stellasterol is a natural product. Stellasterol has high affinity towards Bcl-2 protein (Ki: 118.05 nM). Stellasterol is a weak α-glucosidase inhibitor .
|
-
- HY-121811
-
-
- HY-N12500
-
|
|
Glucosidase
|
Others
|
|
1'-O-Methyl neochebulinate, hydrolyzable tannin, is an α-glucosidase inhibitor with IC50 value of 59.5 μM, isolated from the fruits of Terminalia chebula Retz .
|
-
- HY-137873
-
|
4-Methylumbelliferyl-α-D-Glucose; 4-Methylumbelliferyl-α-D-Glucoside; 4-MU-α-D-Glucopyranoside
|
Fluorescent Dye
|
Others
|
|
4-Methylumbelliferyl-α-D-Glucopyranoside (4-Methylumbelliferyl-α-D-Glucose; 4-Methylumbelliferyl-α-D-Glucoside) is a fluorogenic substrate for α-glucosidase. 4-Methylumbelliferyl-α-D-glucopyranoside is cleaved by α-glucosidase to release the fluorescent moiety 4-methylumbelliferyl (4-MU). 4-MU fluorescence is pH-dependent with excitation maxima of 320 and 360 nm at low (1.97-6.72) and high pH (7.12-10.3), respectively, and an emission maximum ranging from 445 to 455 nm, increasing as pH decreases. 4-Methylumbelliferyl-α-D-glucopyranoside has been used to quantify α-glucosidase activity in infant blood spot samples as a biomarker of Fabry and Pompe diseases, lysosomal storage disorders characterized by a deficiency in the enzyme.
|
-
- HY-16134
-
|
MBI 3253; MDL 28574; MX3253
|
Flavivirus
Dengue virus
Glucosidase
HCV
HIV
|
Infection
|
|
Celgosivir (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
|
-
- HY-16134A
-
|
MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride
|
Flavivirus
Dengue virus
Glucosidase
HCV
HIV
|
Infection
|
|
Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
|
-
- HY-N4095
-
-
- HY-N8018
-
-
- HY-N10606
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC50: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity .
|
-
- HY-N10969
-
|
|
Others
|
Others
|
|
(+)-5,7,4'-Trimethoxyafzelechin is a derivative of (+)-Afzelechin HY-N2821. (+)-Afzelechin is an α-glucosidase activity inhibitor. (+)-Afzelechin can be isolated from rhizomes of Bergenia ligulata .
|
-
- HY-169255
-
-
- HY-B0089
-
|
BAY g 5421
|
Glucosidase
|
Metabolic Disease
|
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N7095
-
|
CTZ
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftezole (CTZ) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole (CTZ) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
- HY-N7096
-
|
CTZ sodium
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
- HY-146128
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC50 of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .
|
-
- HY-N10413
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and α-amylase inhibitor with IC50s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .
|
-
- HY-N6575
-
-
- HY-122782
-
|
Lucialdehyde C
|
Glucosidase
|
Metabolic Disease
Cancer
|
|
Lucidal (Lucialdehyde C) is a natural lanostante-type triterpene aldehyde that shows inhibitory effects against α-glucosidase (Glucosidase) with an IC50 of 0.635 mM. Lucidal has anticancer and antidiabetic effects .
|
-
- HY-N10076
-
-
- HY-N11840
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Mortatarin F (Compound 1) is an inhibitor of α‑glucosidase with an IC50 of 8.7 μΜ. Mortatarin F is an renylated flavonoid that can be isolated from mulberry leaves and can be used for hypoglycemic research .
|
-
- HY-N2809
-
|
|
Others
|
Others
|
|
Acantrifoside E (Compound 8) is a nature compound. Acantrifoside E can be isolated from the 90% ethanol extract of Salacia cochinchinensis. Acantrifoside E has none α-glucosidase inhibitory activity .
|
-
- HY-N9075
-
|
|
Glucosidase
|
Cancer
|
|
9-(4′-Hydroxyphenyl)-2-methoxyphenalen-1-one is a phytoalexin and mixed competitive α-glucosidase inhibitor of Bacillus stearothermophilus (IC50: 3.86 mg/L) .
|
-
- HY-N4195
-
|
Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside
|
Glucosidase
|
Cardiovascular Disease
Metabolic Disease
|
|
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC50 of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .
|
-
- HY-N8947
-
|
|
Endogenous Metabolite
Glucosidase
|
Metabolic Disease
|
|
Glyurallin A (Compound 79) is isolated from the
naturalGlycyrrhiza uralensis. Glyurallin A inhibitsα-Glucosidase(HY-P2802)(IC50=0.3 μM). Glyurallin A
can be used in the study of anti-diabetes .
|
-
- HY-N11841
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Mortatarin G (compound 3) is a prenylated flavonoid, that can be isolated from mulberry leaves. Mortatarin G exhibits good α-glucosidase inhibitory activity, with an IC50 of 20.4±1.4 μM .
|
-
- HY-N12138
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Flaccidoside III is a flavonoid and triterpenoid isolated from the aerial parts of N. sativa (Ranunculaceae). Flaccidoside III inhibits α-Glucosidase (IC50: 256.7 μM) and has potential antioxidant and antidiabetic activities .
|
-
- HY-N7763
-
|
|
Glucosidase
|
Neurological Disease
|
|
Casuarictin is a potent and competitive α-glucosidase inhibitor with an IC50 of 0.21 μg/mL. Casuarictin is a presenilin stabilization factor like protein (PSFL) protein inhibitor. Casuarictin can be used for Alzheimer's disease research .
|
-
- HY-N2703
-
|
|
Glucosidase
|
Metabolic Disease
|
|
6β-Hydroxyipolamiide can be isolated from the methanolic extract of S. jamaicensis leaves. 6β-Hydroxyipolamiide has α-glucosidase inhibitory activity with an IC50 of 539.17 μg/mL .
|
-
- HY-169292
-
|
|
Glucosidase
Reactive Oxygen Species
|
Cancer
|
|
Antitumor agent-188 (compound C6) exerts α-glucosidase inhibitory activity, and antitumor effects.Antitumor agent-188 induces excessive production of ROS to trigger oxidative stress .
|
-
- HY-B0089A
-
|
Bay-g 5421 sulfate
|
Glucosidase
|
Metabolic Disease
|
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N3431
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Kaempferol-7-O-rhamnoside, isolated from Chimonanthus nitens Oliv. Leaves, is a potent α-glucosidase activity inhibitor. Kaempferol-7-O-rhamnoside has the potential for diabetes .
|
-
- HY-N8517
-
|
|
Glucosidase
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
|
Malabaricone B, a naturally occurring plant phenolic, is an orally active α-glucosidase inhibitor with an IC50 of 63.7 µM. Malabaricone B has anticancer, antimicrobial, anti-oxidation and antidiabetic activities .
|
-
- HY-N10002
-
|
|
Phosphatase
Glucosidase
|
Metabolic Disease
|
|
Caffeoyltryptophan is a competitive PTP1B inhibitor, with an IC50 of 16.99 μM. Caffeoyltryptophan can also inhibit α-glucosidase, linoleic acid peroxidation and haemolysis. Caffeoyltryptophan can be used for the research of type 2 diabetes .
|
-
- HY-N10064
-
|
|
Others
|
Metabolic Disease
|
|
Ficusonolide has significant antidiabetic activity with a possible mechanism of interaction with dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1B (PTP-1B), α-glucosidase, and α-amylase.
|
-
- HY-143268
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .
|
-
- HY-N7729
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
- HY-107532
-
|
NN-DNJ; Nonyl-DNJ
|
Glucosidase
|
Metabolic Disease
|
|
N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown .
|
-
- HY-N2821
-
|
|
Glucosidase
|
Metabolic Disease
|
|
(+)-Afzelechin, isolated from rhizomes of Bergenia ligulata, is an alpha-glucosidase activity inhibitor with an ID50 (50% inhibition dose) value of 0.13 mM. (+)-Afzelechin can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia and hyperinsulinemia .
|
-
- HY-N13188
-
|
Michelioside A
|
Glucosidase
|
Cancer
|
|
2'-Rhamnoechinacoside (Michelioside A), a compound of phenylethanoid glycosides, is a α-glucosidase inhibitor with anti-tumor activity, which is derived from Phlomis stewartii. 2'-Rhamnoechinacoside can be used for research of UV-absorbing and cancers .
|
-
- HY-143269
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .
|
-
- HY-161150
-
-
- HY-N7377
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
|
-
- HY-14860
-
|
Duvoglustat
|
Glucosidase
PI3K
|
Metabolic Disease
|
|
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-14860A
-
|
Duvoglustat hydrochloride
|
Glucosidase
PI3K
Bacterial
Antibiotic
|
Infection
Metabolic Disease
|
|
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-126067
-
|
|
Glucosidase
Apoptosis
|
Inflammation/Immunology
|
|
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that inhibits α-glucosidase and acts as a hypoglycemic agent. (-)-Pinoresinol has some anti-inflammatory effects and acts as a chemopreventive agent, inducing increased apoptosis and cell cycle G2/M arrest .
|
-
- HY-N12006
-
|
|
Glucosidase
|
Others
|
|
6,8-Dihydroxy-1,2,7-trimethoxy-3-methylanthraquinone (compound 1) is an anthraquinone α-glucosidase inhibitor (IC50:185 μM), which can be isolated from Cassia seeds .
|
-
- HY-N1186
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Tachioside inhibits nitric oxide production in lipopolysaccharide (HY-D1056)-stimulated RAW 264.7 cells with IC50 value of 12.14 μM. Tachioside has anti-obesity, antioxidant and α-glucosidase inhibitory activities .
|
-
- HY-N1510
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Kaempferol 3-O-gentiobioside is a flavonoid isolated from C. alata leaves with antidiabetic activity. Kaempferol 3-O-gentiobioside possesses activity against α-glucosidase and displays carbohydrate enzyme inhibitory effect with an IC50 of 50.0 µM .
|
-
- HY-N3078
-
|
|
Glucosidase
|
Endocrinology
|
|
p-Hydroxyphenethyl trans-ferulate has anti-hyperglycemic (yeast α-glucosidase, IC50=19.24 ± 1.73 µM), antioxidant, and anti-inflammatory activities . p-Hydroxyphenethyl trans-ferulate shows inhibiting anticancer and serotonergic activity .
|
-
- HY-N10294
-
|
|
HIV
|
Infection
Inflammation/Immunology
|
|
Epicoccone B, firstly reported from C. globosum, exhibits the DPPH free radical scavenging ability with IC50 value of 10.8 μM, and has potent α-glucosidase inhibition with IC50 value of 27.3 μM. Anti-HIV activity .
|
-
- HY-N4095R
-
|
|
Aryl Hydrocarbon Receptor
Glucosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
Brevifolincarboxylic acid (Standard) is the analytical standard of Brevifolincarboxylic acid. This product is intended for research and analytical applications. Brevifolincarboxylic acid is extracted from Polygonum capitatum , has inhibitory effect on the aryl hydrocarbon receptor (AhR) . Brevifolincarboxylic acid is an α-glucosidase inhibitor with an IC50 of 323.46 μM .
|
-
- HY-N7599
-
|
|
Phosphatase
Glucosidase
|
Metabolic Disease
|
|
Chrysophanol triglucoside is an anthraquinone isolated from Cassia obtusifolia, inhibits protein tyrosine phosphatases 1B (PTP1B) and α-glucosidase with IC50s of 80.17 and 197.06 µM, respectively. Chrysophanol triglucoside has the potential for diabetes research .
|
-
- HY-162893
-
|
|
Glucosidase
|
Metabolic Disease
|
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
- HY-163335
-
-
- HY-N6005
-
|
|
Bacterial
|
Infection
Cancer
|
|
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .
|
-
- HY-N11598
-
|
|
Others
|
Metabolic Disease
|
|
α-GLU stands for α-glucosidase. α-GLU hydrolyzes starch and disaccharides via targeting to terminal, non-reducing (1→4)-linked α-D-glucose residues to produce α-glucose. α-GLU is substrate selective .
|
-
- HY-N3542
-
|
|
Glucosidase
|
Cancer
|
|
Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .
|
-
- HY-N7203R
-
|
|
Glucosidase
|
Metabolic Disease
|
|
N-Caffeoyl O-methyltyramine (Standard) is the analytical standard of N-Caffeoyl O-methyltyramine. This product is intended for research and analytical applications. N-Caffeoyl O-methyltyramine is a class of alkaloid isolated from Cuscuta reflexa with strong inhibitory activity against α-glucosidase (IC50 of 103.58 μM) .
|
-
- HY-154995
-
|
|
Others
|
Infection
|
|
N-4′-(p-Trifluoromethylphenyl)butyl-DAB (compound 5g) is an agonit of lysosomal acid α-glucosidase (GAA). N-4′-(p-Trifluoromethylphenyl)butyl-DAB increases intracellular GAA activities dose-dependently, in Pompe patient's fibroblasts with the M519V mutation .
|
-
- HY-N11999
-
|
|
Others
|
Others
|
|
5,4'-Dihydroxy-3,4,3'-trimethoxybibenzyl (compound 8) can be isolated from Dendrobium infundibulum (D. infundibulum). 5,4'-Dihydroxy-3,4,3'-trimethoxybibenzyl has no inhibitory activity against α-glucosidase and pancreatic lipase .
|
-
- HY-B0986
-
|
4-Hexylresorcinol
|
Parasite
Bacterial
Apoptosis
Glucosidase
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
|
Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .
|
-
- HY-N7626
-
|
|
Fungal
Glucosidase
|
Infection
|
|
Eleutherol is a naphthalene isolated from E. americana with antifungal activities . Eleutherol is against yeasts Candida albicans, C. tropicalis, Saccharomyces cerevisiae and Cryptococcus neoformans with MIC values between 7.8 µg/mL and 250 µg/mL . Eleutherol inhibits α-glucosidase function with an IC50>1.00 mM .
|
-
- HY-113133
-
|
|
Glucosidase
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Kojibiose, an orally active prebiotic disaccharide, can specifically inhibit the activity of α-glucosidase I. kojibiose is a proliferation factor for Bifidobacterium, lactic acid bacteria, and eubacteria. kojibiose is a low-calorie sweetener capable of increasing the absorption of iron. Kojibiose exhibits antitoxic activity. Kojibiose reduces hepatic expression of inflammatory markers in vivo .
|
-
- HY-126535
-
|
|
Glucosidase
|
Metabolic Disease
Cancer
|
|
Magnoloside B is an α-glucosidase inhibitor (IC50=0.69 mM), which can be obtained from Magnolia officinalis stem bark. Magnoloside B shows moderate inhibitory activity against MGC-803 and HepG2 cells. Magnoloside B has the potential to study cancer and diabetes .
|
-
- HY-19602
-
|
|
Others
|
Cancer
|
|
Cedefingol is an antitumor compound with α-glucosidase inhibitory activity. Cedefingol was identified together with other compounds in fermented dark tea samples. The biotransformation of cedefingol is related to enzymatic hydrolysis, hydrolysis and biosynthesis. Cedefingol exhibited different bioactivities in samples with different fermentation times. The antioxidant properties of cedefingol showed certain activity in the DPPH model .
|
-
- HY-B0025
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis .
|
-
- HY-161429
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91, 8.89 µM, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .
|
-
- HY-N7683
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Prunetin 5-O-β-D-glucopyranoside is an isoflavone isolated from extracts of Potentilla astracanica. Prunetin 5-O-β-D-glucopyranoside is a potent and uncompetitive inhibitor of α-glucosidase, with an IC50 of 56.05 μg/mL. Prunetin 5-O-β-D-glucopyranoside can be used for the research of type-2 diabetes .
|
-
- HY-N10360
-
|
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM) .
|
-
- HY-N10440
-
|
|
Glucosidase
|
Infection
Inflammation/Immunology
|
|
3-Oxo-hop-22(29)-ene is a yeast α-glucosidase inhibitor. 3-Oxo-hop-22(29)-ene shows a moderate effect on the viability of T. cruzi and L. mexicana. 3-Oxo-hop-22(29)-ene shows marginal activity of anti-inflammatory .
|
-
- HY-N2574
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC50 values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .
|
-
- HY-N1029
-
|
Mangiferitin
|
Glucosidase
PPAR
|
Infection
Inflammation/Immunology
Cancer
|
|
Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC50 of 3.12 μM . Norathyriol inhibits PPARα, PPARβ, and PPARγ with IC50s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.
|
-
- HY-N9283
-
|
|
Reactive Oxygen Species
|
Neurological Disease
Cancer
|
|
1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran, isolated from the edible mushroom Sarcodon leucopus, has antioxidant effects in the DPPH scavenging assay with the IC50 of 28 μM, inhibits malondialdehyde (MDA) with the IC50 of 71 μM, and inhibits α-glucosidase with the IC50 of 6.22 μM .
|
-
- HY-N9051
-
|
|
Glucosidase
|
Inflammation/Immunology
Cancer
|
|
6-Prenylquercetin-3-Me ether is a natural product that can be extracted from G. uralensis leaves.
6-Prenylquercetin-3-Me ether has radical scavenging activity toward DPPH. 6-Prenylquercetin-3-Me ether also has inhibitory activity against α-glucosidase .
|
-
- HY-N7170
-
|
|
Glucosidase
|
Metabolic Disease
|
|
(-)-6β-Hydroxy-5β,8β,9β,10α-cleroda-3,13-dien-16,15-olid-18-oic acid (compound 4) is a α-Glucosidase inhibitor with an IC50 value of 577.7 µM .
|
-
- HY-155961
-
-
- HY-N1839
-
|
|
Apoptosis
Glucosidase
|
Cancer
|
|
3-Hydroxybakuchiol can be isolated from Otholobium mexicanum J. W. Grimes. 3-Hydroxybakuchiol is an electron transport chain (ETC) inhibitor. 3-Hydroxybakuchiol has antitumor activity, and induces tumor cell apoptosis. 3-Hydroxybakuchiol also has moderate inhibitory activity against α-glucosidase (IC50: 345 μM) .
|
-
- HY-N12688
-
|
|
Glucosidase
Amylases
|
Metabolic Disease
|
|
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and α-amylase, with IC50 values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .
|
-
- HY-14860R
-
|
|
Glucosidase
PI3K
|
Metabolic Disease
|
|
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-150723
-
|
|
Glucosidase
|
Metabolic Disease
|
|
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
|
-
- HY-163332
-
|
|
Glucosidase
Dipeptidyl Peptidase
Glutathione Peroxidase
|
Cardiovascular Disease
|
|
MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent .
|
-
- HY-B0986R
-
|
|
Parasite
Bacterial
Apoptosis
Glucosidase
Endogenous Metabolite
|
Infection
Metabolic Disease
Cancer
|
|
Hexylresorcinol (Standard) is the analytical standard of Hexylresorcinol. This product is intended for research and analytical applications. Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .
|
-
- HY-162480
-
|
|
Glucosidase
Phosphatase
|
Endocrinology
|
PTP1B-IN-27 (Compound 7i) is an inhibitor of protein tyrosine phosphatase 1-B (PTP‐1B)(IC50=8.2 µM). PTP1B-IN-27 also inhibits α-Glucosidase (IC50=120 µM) and shows competitive inhibition (Ki=118 µM) .
|
-
- HY-122522
-
|
|
Glucosidase
Parasite
|
Infection
|
|
2-Methylcardol triene is a phenol found in cashew nut shell liquid that inhibits α-glucosidase (IC50=39.6 μM). 2-Methylcardol triene is schistosomicidal, killing 100% of adult S. mansoni worms after 24 hours when used at concentrations of 100 and 200 μM. 2-Methylcardol triene has been used as a starting material for the synthesis of mono- and bis-benzoxazines.
|
-
- HY-N1510R
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Kaempferol 3-O-gentiobioside (Standard) is the analytical standard of Kaempferol 3-O-gentiobioside. This product is intended for research and analytical applications. Kaempferol 3-O-gentiobioside is a flavonoid isolated from C. alata leaves with antidiabetic activity. Kaempferol 3-O-gentiobioside possesses activity against α-glucosidase and displays carbohydrate enzyme inhibitory effect with an IC50 of 50.0 μM .
|
-
- HY-N0057
-
|
3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-126052
-
|
|
COX
Tyrosinase
HDAC
|
Metabolic Disease
Cancer
|
|
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .
|
-
- HY-139663
-
|
|
Glucosidase
|
Infection
|
|
IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase I inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research .
|
-
- HY-N11728
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
|
|
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
|
-
- HY-163463
-
|
|
Phosphatase
Fungal
HIV
Bacterial
|
Infection
Metabolic Disease
|
|
PTP1B-IN-25 (Compound 19) is a PTP1B inhibitor with remarkable antiviral, antibacterial, and antidiabetic activities. PTP1B-IN-25 has IC50 values of 0.37 μM, 8.6 μM, 3.7 μM, and 29 μM against PTP1B, HIV, α-Glucosidase, and methicillin-resistant Staphylococcus aureus (MRSA) respectively .
|
-
- HY-159491
-
|
|
Dipeptidyl Peptidase
Glucosidase
Amylases
|
Metabolic Disease
|
|
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM) .
|
-
- HY-N2025
-
|
|
PPAR
Glucosidase
|
Metabolic Disease
|
|
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
- HY-N2925
-
|
β-Amyron
|
Fungal
COX
PPAR
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
β-Amyrone (β-Amyron) is a triterpene compound which has anti-inflammatory activity through inhibiting the expression of COX-2. β-Amyrone has antifungal activity , as well as antiviral activity against Chikungunya virus. β-Amyrone also inhibits α-glucosidase and acetylcholinesterase (AChE) activity. β-Amyrone can be used in the research of disease like inflammation, infection, and obesity .
|
-
- HY-P99803
-
|
VAL-1221
|
Glucosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-N2574R
-
|
|
Glucosidase
|
Metabolic Disease
|
|
Gitogenin (Standard) is the analytical standard of Gitogenin. This product is intended for research and analytical applications. Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC50 values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .
|
-
- HY-129149
-
|
|
Others
|
Metabolic Disease
|
|
Ganoderic acid SZ is a natural product with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitory activity. Ganoderic acid SZ shows stronger activity than the positive control atorvastatin in inhibiting HMG-CoA reductase. Ganoderic acid SZ exhibits significant inhibition of yeast-derived α-glucosidase with IC50 values achieved at very low concentrations. Ganoderic acid SZ also exhibits cytotoxicity against K562 cells with IC?? values in the range of 10-20 μM .
|
-
- HY-N2278
-
|
Leachianone E
|
Tyrosinase
Glucosidase
|
Cancer
|
|
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .
|
-
- HY-Y0790
-
-
- HY-N8161
-
|
Kaempferol 3,7-diglucoside
|
Glucosidase
Cholinesterase (ChE)
|
Neurological Disease
|
|
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research .
|
-
- HY-N0058
-
|
Isochlorogenic acid C
|
HBV
Endogenous Metabolite
Apoptosis
Glucosidase
|
Infection
|
|
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
|
-
- HY-N10439
-
|
|
Glucosidase
|
Inflammation/Immunology
|
|
3β-Acetoxy-hop-22(29)-ene (compound 1) is a potent anti-inflammatory agent. 3β-Acetoxy-hop-22(29)-ene shows high inhibitory activity of yeast α-glucosidase, with an IC50 of 5.74 μM. 3β-Acetoxy-hop-22(29)-ene inhibits MPO (myeloperoxidase) activity in a dose-dependent manner in mouse ear edema model induced by 12-O-tetradecanoylphorbol acetate (TPA), with an IC50 of 0.23 μmol/ear .
|
-
- HY-N11477
-
|
|
Glucosidase
|
Metabolic Disease
|
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits α-Glucosidase with an IC50 of 1.68 mM .
|
-
- HY-N0057R
-
|
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
3,4-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,4-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-N2025R
-
|
|
PPAR
Glucosidase
|
Metabolic Disease
|
|
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
- HY-168074
-
|
|
Amylases
Glucosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
|
-
- HY-N0946
-
|
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glucosidase
|
Metabolic Disease
|
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
- HY-N0058R
-
|
|
HBV
Endogenous Metabolite
Apoptosis
Glucosidase
|
Infection
|
|
4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
|
-
- HY-Y0790R
-
|
|
Endogenous Metabolite
Apoptosis
DNA/RNA Synthesis
α-synuclein
Lipoxygenase
Opioid Receptor
Interleukin Related
TNF Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W005598
-
|
|
Biochemical Assay Reagents
|
|
2-Hydroxyquinoline is a potent α-glucosidase inhibitor with IC50 values of 64.4, 130.5 µg/mL for α-glucosidase and α-amylase, respectively. 2-Hydroxyquinoline has the potential for the research of diabetes .
|
-
- HY-W826489
-
|
α-Sophorose, 98%
|
Carbohydrates
|
|
D-Glucopyranose, 98% serves as a substrate for various glycosidase enzymes, including α-glucosidase, and is also used in glycobiology research.
|
-
- HY-E70183
-
|
EC:3.2.1.20; GAA
|
Enzyme Substrates
|
|
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99803
-
|
VAL-1221
|
Glucosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
- HY-N7763
-
-
- HY-N2703
-
-
- HY-B0089A
-
-
- HY-N3431
-
-
- HY-N8517
-
-
- HY-N10002
-
-
- HY-N10064
-
-
- HY-N7729
-
-
- HY-N2821
-
-
- HY-N13188
-
-
- HY-N7377
-
-
- HY-14860
-
-
- HY-14860A
-
-
- HY-126067
-
-
- HY-N12006
-
-
- HY-N1186
-
-
- HY-N1510
-
-
- HY-N3078
-
-
- HY-N10294
-
-
- HY-N4095R
-
-
- HY-N7599
-
-
- HY-N6005
-
-
- HY-N3542
-
-
- HY-N7203R
-
-
- HY-N11999
-
-
- HY-B0986
-
-
- HY-N7626
-
-
- HY-113133
-
|
|
Microorganisms
Source classification
|
Glucosidase
|
|
Kojibiose, an orally active prebiotic disaccharide, can specifically inhibit the activity of α-glucosidase I. kojibiose is a proliferation factor for Bifidobacterium, lactic acid bacteria, and eubacteria. kojibiose is a low-calorie sweetener capable of increasing the absorption of iron. Kojibiose exhibits antitoxic activity. Kojibiose reduces hepatic expression of inflammatory markers in vivo .
|
-
- HY-126535
-
-
- HY-B0025
-
-
- HY-N7683
-
-
- HY-N10360
-
-
- HY-N10440
-
-
- HY-N2574
-
-
- HY-N1029
-
-
- HY-N9283
-
|
|
Microorganisms
Source classification
Phenols
Polyphenols
|
Reactive Oxygen Species
|
|
1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran, isolated from the edible mushroom Sarcodon leucopus, has antioxidant effects in the DPPH scavenging assay with the IC50 of 28 μM, inhibits malondialdehyde (MDA) with the IC50 of 71 μM, and inhibits α-glucosidase with the IC50 of 6.22 μM .
|
-
- HY-N9051
-
-
- HY-N7170
-
-
- HY-N1839
-
-
- HY-N12688
-
-
- HY-14860R
-
-
- HY-B0986R
-
-
- HY-N1510R
-
-
- HY-N0057
-
|
3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B
|
Infection
Structural Classification
Caprifoliaceae
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Phenols
Polyphenols
Plants
Endogenous metabolite
Disease Research Fields
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
|
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-126052
-
-
- HY-N11728
-
-
- HY-N2025
-
-
- HY-N2925
-
-
- HY-N2574R
-
|
|
Tribulus terrester Linn.
Structural Classification
Zygophyllaceae
Source classification
Plants
Steroids
|
Glucosidase
|
|
Gitogenin (Standard) is the analytical standard of Gitogenin. This product is intended for research and analytical applications. Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC50 values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .
|
-
- HY-129149
-
|
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source classification
|
Others
|
|
Ganoderic acid SZ is a natural product with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitory activity. Ganoderic acid SZ shows stronger activity than the positive control atorvastatin in inhibiting HMG-CoA reductase. Ganoderic acid SZ exhibits significant inhibition of yeast-derived α-glucosidase with IC50 values achieved at very low concentrations. Ganoderic acid SZ also exhibits cytotoxicity against K562 cells with IC?? values in the range of 10-20 μM .
|
-
- HY-N2278
-
-
- HY-Y0790
-
|
p-Isopropylbenzaldehyde
|
Structural Classification
Classification of Application Fields
Ketones, Aldehydes, Acids
Rudbeckia laciniata L.
Source classification
Umbelliferae
Plants
Endogenous metabolite
Disease Research Fields
Cancer
|
Endogenous Metabolite
Apoptosis
DNA/RNA Synthesis
α-synuclein
Lipoxygenase
Opioid Receptor
Interleukin Related
TNF Receptor
|
|
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
|
-
- HY-N8161
-
-
- HY-N0058
-
-
- HY-N10439
-
-
- HY-N11477
-
|
|
Triterpenes
Structural Classification
Terpenoids
Source classification
Rosaceae
Plants
Rubus ellipticus Smith
|
Glucosidase
|
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits α-Glucosidase with an IC50 of 1.68 mM .
|
-
- HY-N0057R
-
|
|
Structural Classification
Caprifoliaceae
Ketones, Aldehydes, Acids
Source classification
Phenols
Polyphenols
Plants
Endogenous metabolite
|
Glucosidase
Influenza Virus
Apoptosis
Endogenous Metabolite
|
|
3,4-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,4-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL .
|
-
- HY-N2025R
-
|
|
Structural Classification
Flavonoids
Flavones
Source classification
Bignoniaceae
Plants
Oroxylum indicum (Linn.) Bentham ex Kurz
|
PPAR
Glucosidase
|
|
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .
|
-
- HY-N0946
-
|
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Structural Classification
Artemisia selengensis Turcz. ex Bess.
Source classification
Plants
Compositae
Saccharides
Monosaccharides
|
Glucosidase
|
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
- HY-N0058R
-
|
|
Structural Classification
Ketones, Aldehydes, Acids
Source classification
Phenols
Polyphenols
Bowdichia virgilioides
Plants
Compositae
Endogenous metabolite
|
HBV
Endogenous Metabolite
Apoptosis
Glucosidase
|
|
4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
|
-
- HY-Y0790R
-
|
|
Structural Classification
Ketones, Aldehydes, Acids
Rudbeckia laciniata L.
Source classification
Umbelliferae
Plants
Endogenous metabolite
|
Endogenous Metabolite
Apoptosis
DNA/RNA Synthesis
α-synuclein
Lipoxygenase
Opioid Receptor
Interleukin Related
TNF Receptor
|
|
Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-145273
-
|
|
|
Azide
|
|
EB-0150 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.73 and 0.0337 μM, respectively. EB-0150 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0150 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses . EB-0150 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
